Neurological Diseases: Drugs
Commons · Question 119737 · Tabled 10 Mar 2026 · Department of Health and Social Care · Official record
Answered 17 Mar 2026
Question
Asked by Freddie van Mierlo
To ask the Secretary of State for Health and Social Care, what assessment he has made of the effectiveness of the Early Access to Medicines Scheme in facilitating patient access to new treatments for neuromuscular diseases.
Answer
Answered by Zubir Ahmed, 17 Mar 2026
The Medicines and Healthcare products Regulatory Agency (MHRA) supports access to treatments for people living with neuromuscular diseases. The majority of neuromuscular diseases are defined as rare diseases. On the 2 November 2025, the MHRA published a p...